Despite major advancements in the development of safer and more effective anticoagulant
agents, bleeding complications remain a significant concern in the treatment of …

Factor XIa (FXIa) in the intrinsic pathway of the coagulation process has been proven to be
an effective and safe target for anticoagulant discovery with limited or no bleeding …

Abstract Factor XIa (FXIa) is a serine protease homodimer that belongs to the intrinsic
coagulation pathway. FXIa primarily catalyzes factor IX activation to factor IXa, which …

Introduction: Anticoagulants are the mainstay for prevention and/or treatment of thrombotic
disorders. Each clinically used anticoagulant is associated with significant adverse …

Direct oral anticoagulants (DOACs) are small molecule inhibitors of the coagulation
proteases thrombin and factor Xa that demonstrate comparable efficacy to warfarin for …

Immune regulation is a complex biological signaling pathway in which several classes of
biomolecules and small molecules play a complacent role to mediate this process …

With the introduction of thrombin and factor Xa inhibitors to the oral anticoagulant market,
significant improvements in both efficacy and safety have been achieved. Early clinical and …

Background The plasma protease factor XIa (FXIa) has become a target of interest for
therapeutics designed to prevent or treat thrombotic disorders. Methods We used a solution …

Coagulation factor XIII (FXIII) acts as a fine fulcrum in blood plasma that maintains the
balance between bleeding and thrombosis by covalently crosslinking the pre-formed fibrin …

Abstract Background Human factor XIa (FXIa) is an actively pursued target for development
of safer anticoagulants. Our long‐standing hypothesis has been that allosterism originating …